Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...

The Phase I trial conducted concurrently in China and the United States, was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity ...

became the first drug to be approved by the FDA for the treatment of the rare cancer malignant pleural mesothelioma. Its accelerated approval for the second-line treatment of non-small-cell lung ...

At present, education is not considered a high-risk industry for malignant mesothelioma. Off Education employees do not fit the typical patient profile of mesothelioma and asbestos exposure. Despite ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...